Logo image
A phase II randomized controlled trial of tiopronin for aneurysmal subarachnoid hemorrhage
Journal article   Peer reviewed

A phase II randomized controlled trial of tiopronin for aneurysmal subarachnoid hemorrhage

Natasha Ironside, Brandon Christophe, Samuel Bruce, Amanda M. Carpenter, Trae Robison, Nina Yoh, Serge Cremers, Donald Landry, Hans-Peter Frey, Ching-Jen Chen, …
Journal of Neurosurgery, Vol.133(2)
2020

Abstract

3 aminopropanal biological marker neurotoxin placebo tiopronin unclassified drug acidosis adult adult respiratory distress syndrome Article Barthel index brain ventriculitis cardiopulmonary arrest cerebrospinal fluid level clinical outcome controlled study deterioration double blind procedure drug efficacy drug withdrawal female heart arrhythmia hospital mortality human hypernatremia hyponatremia hypoxia larynx edema leukopenia major clinical study male mental deterioration middle aged multicenter study nausea phase 2 clinical trial priority journal prospective study pyrexia idiopathica randomized controlled trial Rankin scale rash seizure subarachnoid hemorrhage survival thrombocytopenia thromboembolism upregulation
OBJECTIVE Delayed cerebral ischemia (DCI) is a significant contributor to poor outcomes after aneurysmal subarachnoid hemorrhage (aSAH). The neurotoxin 3-aminopropanal (3-AP) is upregulated in cerebral ischemia. This phase II clinical trial evaluated the efficacy of tiopronin in reducing CSF 3-AP levels in patients with aSAH. METHODS In this prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial, 60 patients were assigned to receive tiopronin or placebo in a 1:1 ratio. Treatment was commenced within 96 hours after aSAH onset, administered at a dose of 3 g daily, and continued until 14 days after aSAH or hospital discharge, whichever occurred earlier. The primary efficacy outcome was the CSF 3-AP level at 7 ± 1 days after aSAH. RESULTS Of the 60 enrolled patients, 29 (97%) and 27 (93%) in the tiopronin and placebo arms, respectively, received more than one dose of the study drug or placebo. At post-aSAH day 7 ± 1, CSF samples were available in 41% (n = 12/29) and 48% (n = 13/27) of patients in the tiopronin and placebo arms, respectively. No difference in CSF 3-AP levels at post-aSAH day 7 ± 1 was observed between the study arms (11 ± 12 nmol/mL vs 13 ± 18 nmol/mL; p = 0.766). Prespecified adverse events led to early treatment cessation for 4 patients in the tiopronin arm and 2 in the placebo arm. CONCLUSIONS The power of this study was affected by missing data. Therefore, the authors could not establish or refute an effect of tiopronin on CSF 3-AP levels. Additional observational studies investigating the role of 3-AP as a biomarker for DCI may be warranted prior to its use as a molecular target in future clinical trials. ©AANS 2020, except where prohibited by US copyright law

Metrics

6 Record Views

Details

Logo image